Different strategies for screening and prevention of type 2 diabetes in adults: Cost effectiveness analysis

BMJ

Volumn 336, Issue 7654, 2008, Pages 1180-1184

  Gillies, Clare L ^a   Lambert, Paul C ^a   Abrams, Keith R ^a   Sutton, Alex J ^a   Cooper, Nicola J ^a   Hsu, Ron T ^a   Davies, Melanie J ^a   Khunti, Kamlesh ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA EXTRACTION; DEATH; DECISION MAKING; DECISION TREE; EARLY DIAGNOSIS; EVALUATION; IMPAIRED GLUCOSE TOLERANCE; INFORMATION RETRIEVAL; LIFESTYLE MODIFICATION; MASS SCREENING; MEDICAL LITERATURE; MONEY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; PROBABILITY; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SCREENING TEST; SENSITIVITY ANALYSIS; SIMULATION; BLOOD; COST OF ILLNESS; ECONOMICS; HUMAN; METABOLISM; MIDDLE AGED; QUALITY OF LIFE;

GLYCOSYLATED HEMOGLOBIN;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION TREES; DIABETES MELLITUS, TYPE 2; EARLY DIAGNOSIS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS;

EID: 44449126657     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39545.585289.25     Document Type: Article

References (29)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence numerical estimates, and projections. Diabetes Care 1998;21:1414-31.
2. DECODE study group, European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999;354:617-21.
3. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance. BMJ 2007;334:299-302.
4. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess 2007;11:1-125.
5. Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004;8:1-182.
6. Caro JJ, Getsios D, Caros I, Klittich WS, O'Brien JA. Economic evaluation of therapeutic interventions to prevent type 2 diabetes in Canada. Diabet Med 2004;21:1229-36.
7. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and costeffectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143:251-64.
8. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323-32.
9. Icks A, Rathmann W, Haastert B, Gandjour A, Holle R, John J, et al. Clinical and cost-effectiveness of primary prevention of type 2 diabetes in a "real world" routing healthcare setting: model based on the KORA Survey 2000. Diabet Med 2007;24:473-80.
10. Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther 2004;26:304-21.
11. Segal L, Dalton AC, Richardson J. Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus. Health Promot Int 1998;13:197-209.
12. CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998;280:1757-63.
13. Chen THH, Yen MF, Tung TH. A computer simulated model for costeffectiveness analysis of mass screening for type 2 diabetes mellitus. Diabetes Res Clin Pract 2001;54:S37-42.
14. Glumer C, Yuyun M, Griffin S, Farewell D, Spiegelhalter D, Kinmouth AL, et al. What determines the cost-effectiveness of diabetes screening? Diabetologia 2006;49:1536-44.
15. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004;140:756-8.
16. Cooper NJ, Sutton AJ, Abrams KR, Turner D, Wailoo A. Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. Health Econ 2004;13:203-26.
17. Spiegelhalter DJ, Thomas A, Best NG, Gilks W. BUGS: Bayesian inference using Gibbs sampling, version 1.4.1. Cambridge: MRC Biostatistics Unit, 2003.
18. Davies MJ, Tringham JR, Jarvis J, Skinner TC, Farooqi AM, Khunti K. Systematic screening for type 2 diabetes mellitus: results of a large population based study targeting those with conventional risk factors. Diabet Med 2005;22(suppl 2):99.
19. Harris MI, Klein R, Welborn TA, Knuiman MW, Harris MI, Klein R, et al. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992;15:815-9.
20. DECODE Study Group, European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999;354:617-21.
21. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH, Rossing P, Hougaard P, et al. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 1996;313:779-84.
22. Turner RC, Holman RR, Mathews DR, Oakes SF, Bassett PA, Stratton IM, et al. Study design, progress and performance (UKPDS VIII). Diabetologia 1991;34:877-90.
23. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
24. Srinivasan BT, Davies MJ, Webb D, Healey E, Farooqi A, Hiles S, et al. Baseline charactersitics and risk of progression from prediabetes to type 2 diabetes in a multiethnic, population based screening. Diabetic Med 2007;24(suppl 1):51.
25. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;4:340-9.
26. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS) outcomes model (UKPDS 68). Diabetologia 2004;47:1747-59.
27. Gulliford MC, Charlton J, Latinovic R. Increased utilization of primary care 5 years before diagnosis of type 2 diabetes. Diabetes Care 2005;28:47-52.
28. Curtis L, Netten A. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent, 2006.
29. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes. Diabetologia 2004;48:868-77.